Hologic, Inc. (NASDAQ:HOLX) is Black Creek Investment Management Inc.'s 6th Largest Position

Black Creek Investment Management Inc. lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,320,590 shares of the medical equipment provider's stock after selling 339,651 shares during the period. Hologic accounts for 7.9% of Black Creek Investment Management Inc.'s holdings, making the stock its 6th biggest position. Black Creek Investment Management Inc. owned about 1.03% of Hologic worth $167,291,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of HOLX. Benson Investment Management Company Inc. acquired a new position in Hologic in the 4th quarter valued at $4,832,000. Principal Financial Group Inc. increased its position in shares of Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after buying an additional 1,606 shares during the period. Clean Yield Group grew its holdings in Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after acquiring an additional 7,266 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Hologic by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock valued at $110,700,000 after acquiring an additional 238,222 shares in the last quarter. Finally, Stifel Financial Corp increased its stake in Hologic by 115.8% in the third quarter. Stifel Financial Corp now owns 20,354 shares of the medical equipment provider's stock valued at $1,658,000 after purchasing an additional 10,924 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Hologic Price Performance

NASDAQ HOLX traded down $1.36 during trading on Wednesday, reaching $56.50. The company's stock had a trading volume of 3,256,993 shares, compared to its average volume of 1,929,097. The stock has a market capitalization of $12.68 billion, a PE ratio of 17.82, a P/E/G ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a fifty day moving average of $61.87 and a 200 day moving average of $71.15. Hologic, Inc. has a one year low of $56.06 and a one year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several recent research reports. William Blair restated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Raymond James reiterated an "outperform" rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Stephens restated an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Finally, Royal Bank of Canada dropped their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.